heterodimeric jak-stat activation mechanism persistence jak2 inhibitor therapy 
identification somatic activating mutations jak2 refs thrombopoietin receptor gene mpl patients myeloproliferative neoplasm mpn led clinical development jak2 kinase inhibitors jak2 inhibitor therapy improves mpn-associated splenomegaly systemic symptoms significantly decrease eliminate mpn clone patients mpn therefore sought characterize mechanisms mpn cells persist despite chronic inhibition jak2 show jak2 inhibitor persistence associated reactivation jak-stat signalling heterodimerization activated jak2 jak1 tyk2 consistent activation jak2 trans jak kinases phenomenon reversible: jak2 inhibitor withdrawal associated resensitization jak2 kinase inhibitors reversible changes jak2 expression saw increased jak2 heterodimerization sustained jak2 activation cell lines murine models patients treated jak2 inhibitors rna interference pharmacological studies show jak2-inhibitor-persistent cells remain dependent jak2 protein expression consequently therapies result jak2 degradation retain efficacy persistent cells may provide additional benefit patients jak2-dependent malignancies treated jak2 inhibitors 
